Quantum Genomics Société Anonyme (QNNTF)
USD 0.1
(0.0%)
USD 0.1
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -916.7 Thousand USD | 87.56% |
| 2022 | -7.36 Million EUR | 35.78% |
| 2021 | -11.47 Million USD | 64.31% |
| 2020 | -32.14 Million USD | -421.52% |
| 2019 | -6.16 Million EUR | 63.54% |
| 2018 | -16.9 Million USD | -131.28% |
| 2017 | -7.3 Million USD | -215.44% |
| 2016 | -2.31 Million USD | 53.14% |
| 2015 | -4.94 Million USD | -39469.61% |
| 2014 | -12.49 Thousand USD | -101.26% |
| 2013 | 990.39 Thousand USD | 104.9% |
| 2012 | 483.36 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q3 | -830.54 Thousand EUR | -651.06% |
| 2023 Q4 | -830.54 Thousand EUR | 0.0% |
| 2023 FY | -916.7 Thousand USD | 87.56% |
| 2023 Q2 | 150.71 Thousand EUR | 0.0% |
| 2023 Q1 | 150.71 Thousand EUR | 102.05% |
| 2022 Q1 | -16.18 Million EUR | -58.38% |
| 2022 Q4 | -7.36 Million EUR | 0.0% |
| 2022 FY | -7.36 Million EUR | 35.78% |
| 2022 Q3 | -7.36 Million EUR | 54.47% |
| 2022 Q2 | -16.18 Million EUR | 0.0% |
| 2021 Q1 | -16.86 Million EUR | 36.13% |
| 2021 FY | -11.47 Million USD | 64.31% |
| 2021 Q4 | -10.21 Million EUR | 0.0% |
| 2021 Q3 | -10.21 Million EUR | 39.41% |
| 2021 Q2 | -16.86 Million EUR | 0.0% |
| 2020 Q1 | -5.83 Million EUR | 5.25% |
| 2020 Q2 | -5.83 Million EUR | 0.0% |
| 2020 Q4 | -26.4 Million EUR | 0.0% |
| 2020 FY | -32.14 Million USD | -421.52% |
| 2020 Q3 | -26.4 Million EUR | -352.13% |
| 2019 Q1 | -6.62 Million EUR | 55.2% |
| 2019 FY | -6.16 Million EUR | 63.54% |
| 2019 Q3 | -6.16 Million EUR | 6.96% |
| 2019 Q2 | -6.62 Million EUR | 0.0% |
| 2019 Q4 | -6.16 Million EUR | 0.0% |
| 2018 Q3 | -14.78 Million EUR | -148.04% |
| 2018 Q1 | -5.96 Million EUR | 2.06% |
| 2018 Q2 | -5.96 Million EUR | 0.0% |
| 2018 Q4 | -14.78 Million EUR | 0.0% |
| 2018 FY | -16.9 Million USD | -131.28% |
| 2017 Q2 | -2.31 Million EUR | 0.0% |
| 2017 FY | -7.3 Million USD | -215.44% |
| 2017 Q4 | -6.08 Million EUR | 0.0% |
| 2017 Q1 | -2.31 Million EUR | -5.52% |
| 2017 Q3 | -6.08 Million EUR | -162.58% |
| 2016 Q3 | -2.19 Million EUR | 47.99% |
| 2016 Q4 | -2.19 Million EUR | 0.0% |
| 2016 FY | -2.31 Million USD | 53.14% |
| 2016 Q2 | -4.22 Million EUR | 0.0% |
| 2016 Q1 | -4.22 Million EUR | 7.19% |
| 2015 Q3 | -4.55 Million EUR | -333.7% |
| 2015 FY | -4.94 Million USD | -39469.61% |
| 2015 Q1 | -1.04 Million EUR | -10063.0% |
| 2015 Q4 | -4.55 Million EUR | 0.0% |
| 2015 Q2 | -1.04 Million EUR | 0.0% |
| 2014 Q1 | -890.72 Thousand EUR | -223.93% |
| 2014 Q4 | -10.32 Thousand EUR | 0.0% |
| 2014 Q2 | -890.72 Thousand EUR | 0.0% |
| 2014 Q3 | -10.32 Thousand EUR | 98.84% |
| 2014 FY | -12.49 Thousand USD | -101.26% |
| 2013 Q3 | 718.74 Thousand EUR | 0.0% |
| 2013 FY | 990.39 Thousand USD | 104.9% |
| 2013 Q4 | 718.74 Thousand EUR | 0.0% |
| 2013 Q1 | 53.56 Thousand EUR | 0.0% |
| 2012 FY | 483.36 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 179.339% |
| CSL Limited | 10.52 Billion USD | 100.009% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 105.816% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 122.261% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 328.123% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 102.142% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 85.46% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 198.87% |
| Mesoblast Limited | 55.85 Million USD | 101.641% |
| Marizyme, Inc. | 18.56 Million USD | 104.937% |
| Genus plc | 190.6 Million USD | 100.481% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 141.001% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 175.518% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 234.81% |
| ContraFect Corporation | -6.02 Million USD | 84.787% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 780.864% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| IMV Inc. | 7.67 Million USD | 111.951% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 116.662% |
| MultiCell Technologies, Inc. | 90.04 USD | 1018213.061% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -24.896% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 107.081% |
| EV Biologics, Inc. | 1.36 Million USD | 167.012% |
| Q BioMed Inc. | 4.06 Million USD | 122.579% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 103.0% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 190.969% |
| Biomind Labs Inc. | 711.4 Thousand USD | 228.859% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 107.158% |
| Skye Bioscience, Inc. | -5.72 Million USD | 83.978% |
| SQZ Biotechnologies Company | -36.23 Million USD | 97.47% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 755.71% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 116.23% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 140.884% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 4714.23% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 247.295% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 100.835% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 206.564% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 141.631% |
| GB Sciences, Inc. | 1.74 Million USD | 152.464% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -398.786% |
| argenx SE | -2.02 Billion USD | 99.955% |
| HST Global, Inc. | 96.79 Thousand USD | 1047.082% |
| Halberd Corporation | 144.72 Thousand USD | 733.432% |
| Enzolytics Inc. | 981.65 Thousand USD | 193.384% |
| Resverlogix Corp. | 6.45 Million USD | 114.21% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -36.194% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 102.111% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 101.514% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 98.05% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 145.849% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 112.964% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 354.847% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 133.844% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 89.63% |
| AVAX Technologies, Inc. | -5.9 Million USD | 84.471% |
| ONE Bio Corp. | 9.04 Million USD | 110.141% |
| Zenith Capital Corp. | 10.06 Thousand USD | 9208.794% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.914% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 557.367% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 138.42% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 657.239% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -4904.416% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 544.536% |
| Agentix Corp. | 37.63 Thousand USD | 2536.047% |
| Adynxx, Inc. | - USD | Infinity% |
| Kadimastem Ltd | -253.1 Thousand USD | -262.19% |
| Helix BioMedix, Inc. | -2.57 Million USD | 64.331% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 104.521% |
| BioStem Technologies, Inc. | 4.47 Million USD | 120.499% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 555.499% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -69877.786% |
| LadRx Corporation | -2.03 Million USD | 54.985% |
| Cell Source, Inc. | 9.23 Million USD | 109.93% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -4391.91% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 244.326% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 244.326% |
| NovAccess Global Inc. | 2.17 Million USD | 142.081% |
| Affymax, Inc. | -5.59 Million USD | 83.621% |
| Itoco Inc. | 228.3 Thousand USD | 501.528% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 774.105% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 118.493% |
| CytoDyn Inc. | 20.26 Million USD | 104.524% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -141586.09% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -9790.757% |
| Qrons Inc. | 351.42 Thousand USD | 360.853% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 111.896% |
| SYBLEU INC | 473.71 Thousand USD | 293.515% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -267.242% |
| Rebus Holdings, Inc. | 305 Thousand USD | 400.56% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 120.568% |
| Mobile Lads Corp. | 484.23 Thousand USD | 289.312% |
| International Stem Cell Corporation | 2.59 Million USD | 135.394% |
| Bioxytran, Inc. | 1.89 Million USD | 148.275% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 1568.779% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 142.034% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 126.695% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 110.718% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 218.651% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 26.663% |
| Neutra Corp. | 52.18 Thousand USD | 1856.585% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 63.17% |
| PureTech Health plc | -167.19 Million USD | 99.452% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -274.307% |
| IXICO plc | -4.44 Million USD | 79.375% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 106.935% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 101.671% |
| CSL Limited | 10.52 Billion USD | 100.009% |
| Cellectis S.A. | -43.81 Million USD | 97.908% |